Evolus

MedTech Marketplace Pipeline Medical Now Provides Jeuveau for the Treatment of Glabellar Lines

MedTech Marketplace Pipeline Medical Now Provides Jeuveau for the Treatment of Glabellar Lines

Pipeline Medical aggregates medical supplies and pharmaceuticals from various manufacturers, suppliers and distributors, providing customers with streamlined purchasing experience.

Evolus Expands International Presence with Nuceiva Launch in Great Britain

Evolus Expands International Presence with Nuceiva Launch in Great Britain

Evolus launched commercial operations in Great Britain and shipped the first customer order for Nuceiva (botulinum toxin type A) last month.

Evolus named Sandra Beaver, with over 20 years of financial experience, as its new CFO.

Evolus Promotes Sandra Beaver as Chief Financial Officer

Sandra Beaver brings more than 20 years of financial experience, driving company growth through strategic planning, long-range forecasting and more.

woman receiving Botox injection in forehead

Evolus Completes Patient Enrollment for Extra-Strength Glabellar Line Study

The study evaluates an "extra-strength" dose of Jeuveau for its safety, efficacy, duration of effect and potential clinical tradeoffs for patients when using the longer duration option.

Photo of gold party streamers and confetti.

Evolus Celebrates Third Anniversary of Jeuveau Launch

Jeuveau (prabotulinumtoxinA-xvfs) has been available in the U.S. for three years as the injectable's parent company, Evolus, continues national and international expansion plans.

Evolus has enrolled the first patient in its phase III Jeuveau “extra-strength” dose study.

First Patient Enrolled in Evolus Jeuveau “Extra-Strength” Dose Trial

“Enrolling the first patient in the ‘extra-strength’ trial marks an important milestone for Evolus—we are now one step closer to the possibility of fulfilling an unmet need in the aesthetic neurotoxin segment.”